Table 1.
Patient characteristics
| Number | N (%) |
|---|---|
|
Total |
106 (100) |
|
Age at diagnosis, median |
57 |
|
FIGO stage |
|
| I |
8 (8) |
| II |
8 (8) |
| III |
76 (71) |
| IV |
14 (13) |
|
Histopathological subtype |
|
| Serous* |
94 (89) |
| Endometrioid |
5 (4) |
| Serous + clear cell (mixed) |
1 (1) |
| Transitiocellular carcinoma |
1 (1) |
| Carcinosarcoma |
1 (1) |
| Adenocarcinoma |
1 (1) |
| Borderline (with invasive implants) |
3 (3) |
|
Number of prior chemotherapy regimens |
|
| Median |
4 |
| Range |
2 - 7 |
|
Interval from last chemotherapy regimens |
|
| Median |
1.8 |
| Range |
0.3-14.7 months |
|
Bevacizumab infusions |
|
| Median |
4.5 |
| Mean |
7.1 |
| Range |
1 – 64** |
| ≤ 2 cycles |
22 (21) |
| ≥ 9 cycles |
29 (27) |
|
Performance status at start of bevacizumab treatment |
|
| 0 |
40 (38) |
| 1 |
52 (49) |
| 2 |
13 (12) |
| 3 |
1 (1) |
|
Baseline VEGF, median (range) |
504 (27–1847) |
|
Baseline PDGF-AA, median (range) |
2074.25 (207 – 5476.5) |
|
Baseline PDGF-BB, median (range) |
7789 (670–28487) |
| Baseline FGF2, median (range) | 60 (8–234) |
* including primary peritoneal and fallopian cancer.
** still receiving bevacizumab.